HEALEY ALS Platform Trial

Weekly Q&A – Jan 13, 2022



MGH	MASSACHUSETTS
1811	GENERAL HOSPITAL
1811	GENERAL HOSPITAL



Sean M. Healey & AMG Center for ALS at Mass General







































The Arthur M. Blank FAMILY FOUNDATION





Guest Speaker

Sharon Hesterlee, PhD Chief Research Officer Muscular Dystrophy Association (MDA)



Working to Defeat ALS

The Muscular Dystrophy Association is an Umbrella Organization Covering Over 300 Neuromuscular Diseases, including ALS


1/13/2022



Muscular Dystrophy Association

\$170M investment by MDA has fueled critical breakthroughs in ALS

In the 1950's Eleanor Gehrig requested MDA's help in the fight against ALS







MDA Integrated Research and Clinical Resources



- MDA Monthly Report news
- Advisory Meetings
- COVID19 materials



- 50 exhibitors
- 30 sessions with CME Credits
- 12 Industry Forums
- Register free for virtual attendance • https://forms.office.com/r/H1zTnjvgSw

≽5

MDA ALS Focus: Care, Research and Data

Care



MDA Maintains 150 neuromuscular specialty Care Centers across the US-

48 are focused specifically on ALS

Research


\$170M in ALS Research Grants Made to Date

Data

MDA MOVR Data Hub contains rigorous clinical data from 2000 Participants with ALS

Example of Research Grant: ALS Platform Trial: Accelerating the Path to Effective Treatments





FROM SYMPTOM ONSET

6

MDA ALS Focus: Advocacy and Education

Advocacy

www.votervoice.net/MDA/home

Three Leading ALS Organizations Celebrate President Bident Signing the ACT for ALS into Law December 23, 2021



Current Issues



Access to Care and Therapies from Day 1

Early detection and intervention of neuromuscular diseases is critical in order to deliver adequate and appropriate healthcare. Continue reading \rightarrow



Accelerating Therapy Development

We are committed to working with key stakeholders, including the US Food and Drug Administration (FDA), to help accelerate development of life-changing therapies. **Continue** reading →




MDA works every day to ensure that members of the neuromuscular community are able to learn, work, travel, and socialize without discrimination. Continue reading \rightarrow

MDA Advocacy Statements and Communications to Policy Makers

Learn more about MDA's communication with policy makers. Continue reading \rightarrow

Education

www.mda.org.community-ed




MDA Facebook Live Event: Care and Res

ALS Care and Research Update Facebook Live Event

MDA Engage: Amyotrophic Lateral Sclerosis (ALS) May 12-13, 2021 Live, Virtual Webinar Watch Recorded Seminar Here



The HEALEY ALS Platform Trial is a Perpetual Adaptive Trial



Regimens A, B, C and D completed enrollment!

162 individuals were randomized within Regimen A
167 individuals were randomized within Regimen B
161 individuals were randomized within Regimen C
163 individuals were randomized within Regimen D



> 300 participants have entered the Open Label Extension (OLE)

=Thank You =

This breakthrough trial would not be possible without your partnership

Send us webinar ideas!

Upcoming Guest Speaker:

Jan 20th- Senda Ajroud-Driss, MD (Northwestern University, Chicago IL)

Weekly webinar registration:



ALS Link sign-up:

